EBX 102 02
Alternative Names: EBX-102-02Latest Information Update: 26 Nov 2024
Price :
$50 *
At a glance
- Originator EnteroBiotix
- Class Anti-inflammatories
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Irritable bowel syndrome; Transplant rejection
Most Recent Events
- 18 Nov 2024 EnteroBiotix completes enrolment in the phase II TrIuMPH trial for Irritable bowel syndrome in United Kingdom (PO)
- 03 Apr 2024 Phase-II clinical trials in Irritable bowel syndrome in United Kingdom (PO)
- 03 Mar 2024 Phase-II clinical trials in Transplant rejection (Prevention) (PO), prior to April 2024 (EnteroBiotix pipeline, April 2024)